Literature DB >> 21901695

Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification.

Laura Amato1, Silvia Minozzi, Marina Davoli, Simona Vecchi.   

Abstract

BACKGROUND: Different pharmacological approaches aimed at opioid detoxification are effective. Nevertheless a majority of patients relapse to heroin use, and relapses are a substantial problem in the rehabilitation of heroin users. Some studies have suggested that the sorts of symptoms which are most distressing to addicts during detoxification are psychological rather than physiological symptoms associated with the withdrawal syndrome.
OBJECTIVES: To evaluate the effectiveness of any psychosocial plus any pharmacological interventions versus any pharmacological alone for opioid detoxification, in helping patients to complete the treatment, reduce the use of substances and improve health and social status. SEARCH STRATEGY: We searched the Cochrane Drugs and Alcohol Group trials register (June 2011), Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 6, 2011), PUBMED (1996 to June 2011); EMBASE (January 1980 to June 2011); CINAHL (January 2003 to June 2008); PsycINFO (1985 to April 2003) and reference list of articles. SELECTION CRITERIA: Randomised controlled trials and controlled clinical trial which focus on any psychosocial associated with any pharmacological intervention aimed at opioid detoxification. People less than 18 years of age and pregnant women were excluded. DATA COLLECTION AND ANALYSIS: Two authors independently assessed trials quality and extracted data. MAIN
RESULTS: Eleven studies, 1592 participants, fulfilled the criteria of inclusion and were included in the review. The studies considered five different psychosocial interventions and two pharmacological treatments (methadone and buprenorphine). Compared to any pharmacological treatment alone, the association of any psychosocial with any pharmacological was shown to significantly reduce dropouts RR 0.71 (95% CI 0.59 to 0.85), use of opiate during the treatment, RR 0.82 (95% CI 0.71 to 0.93), at follow up RR 0.66 (95% IC 0.53 to 0.82) and clinical absences during the treatment RR 0.48 (95%CI 0.38 to 0.59). Moreover, with the evidence currently available, there are no data supporting a single psychosocial approach. AUTHORS'
CONCLUSIONS: Psychosocial treatments offered in addition to pharmacological detoxification treatments are effective in terms of completion of treatment, use of opiate, participants abstinent at follow-up and clinical attendance. The evidence produced by this review is limited due to the small number of participants included in the studies, the heterogeneity of the assessment or the lack of detailed outcome information that prevented the possibility of cumulative analysis for several outcomes. Nevertheless it seems desirable to develop adjunct psychosocial approaches that might make detoxification more effective.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21901695     DOI: 10.1002/14651858.CD005031.pub4

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  41 in total

1.  Tapering off and returning to buprenorphine maintenance in a primary care Office Based Addiction Treatment (OBAT) program.

Authors:  Zoe M Weinstein; Gabriela Gryczynski; Debbie M Cheng; Emily Quinn; David Hui; Hyunjoong W Kim; Colleen Labelle; Jeffrey H Samet
Journal:  Drug Alcohol Depend       Date:  2018-06-19       Impact factor: 4.492

Review 2.  Opioid use and misuse: health impact, prevalence, correlates and interventions.

Authors:  Maria Bolshakova; Ricky Bluthenthal; Steve Sussman
Journal:  Psychol Health       Date:  2019-06-08

3.  Opioid medication misuse among unhealthy drinkers.

Authors:  Gerald Cochran; Rebecca McCarthy; Adam J Gordon; Ralph E Tarter
Journal:  Drug Alcohol Depend       Date:  2017-07-14       Impact factor: 4.492

4.  County-level access to opioid use disorder medications in medicare Part D (2010-2015).

Authors:  Amanda J Abraham; Grace Bagwell Adams; Ashley C Bradford; William D Bradford
Journal:  Health Serv Res       Date:  2019-01-21       Impact factor: 3.402

5.  Overcoming Barriers to Adopting and Implementing Pharmacotherapy: the Medication Research Partnership.

Authors:  Raina Croff; Kim Hoffman; Kelly Alanis-Hirsch; Jay Ford; Dennis McCarty; Laura Schmidt
Journal:  J Behav Health Serv Res       Date:  2019-04       Impact factor: 1.505

6.  Defining dosing pattern characteristics of successful tapers following methadone maintenance treatment: results from a population-based retrospective cohort study.

Authors:  Bohdan Nosyk; Huiying Sun; Elizabeth Evans; David C Marsh; M Douglas Anglin; Yih-Ing Hser; Aslam H Anis
Journal:  Addiction       Date:  2012-05-08       Impact factor: 6.526

7.  Randomized clinical trial comparing buprenorphine/naloxone and methadone for the treatment of patients with failed back surgery syndrome and opioid addiction.

Authors:  Anne M Neumann; Richard D Blondell; Rachel A Hoopsick; Gregory G Homish
Journal:  J Addict Dis       Date:  2019-11-27

8.  Optimizing Pregnancy Treatment Interventions for Moms (OPTI-Mom): A Pilot Study.

Authors:  Gerald T Cochran; Valerie Hruschak; Walitta Abdullah; Elizabeth Krans; Antoine B Douaihy; Stephanie Bobby; Rachel Fusco; Ralph Tarter
Journal:  J Addict Med       Date:  2018 Jan/Feb       Impact factor: 3.702

Review 9.  Buprenorphine Treatment for Adolescents and Young Adults With Opioid Use Disorders: A Narrative Review.

Authors:  Jacob T Borodovsky; Sharon Levy; Marc Fishman; Lisa A Marsch
Journal:  J Addict Med       Date:  2018 May/Jun       Impact factor: 3.702

10.  Feasibility of a Supportive Other Intervention for Opiate-Dependent Patients Entering Inpatient Detoxification.

Authors:  Yael Chatav Schonbrun; Bradley J Anderson; Jennifer E Johnson; Michael D Stein
Journal:  J Psychoactive Drugs       Date:  2016-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.